Viridian Therapeutics, Inc.VRDNNASDAQ
Loading
Cash Flow Under PressureContracting
Percentile Rank0
Studio
Year-over-Year Change

Operating cash flow minus capital expenditures

Latest
$-276.89M
↓ 185% vs avg
Percentile
P0
Near historical low
Streak
5 yr
Consecutive declineContracting
Average
$-97.32M
Historical baseline
PeriodValueYoY Change
2025$-276.89M-18.9%
2024$-232.83M-25.8%
2023$-185.07M-95.6%
2022$-94.64M-72.3%
2021$-54.92M-84.2%
2020$-29.82M+17.5%
2019$-36.14M-32.4%
2018$-27.29M+4.0%
2017$-28.41M-292.8%
2016$-7.23M-